The canonical set of amino acids leads to an exceptionally wide range of protein functionality. Nevertheless, the set of residues still imposes limitations on potential protein applications. The incorporation of noncanonical amino acids can enlarge this scope. There are two complementary approaches for the incorporation of noncanonical amino acids. For site-specific incorporation, in addition to the endogenous canonical translational machineries, an orthogonal aminoacyl-tRNA-synthetase-tRNA pair must be provided that does not interact with the canonical ones. Consequently, a codon that is not assigned to a canonical amino acid, usually a stop codon, is also required. This genetic code expansion enables the incorporation of a noncanonical amino acid at a single, given site within the protein. The here presented work describes residue-specific incorporation where the genetic code is reassigned within the endogenous translational system. The translation machinery accepts the noncanonical amino acid as a surrogate to incorporate it at canonically prescribed locations, i.e., all occurrences of a canonical amino acid in the protein are replaced by the noncanonical one. The incorporation of noncanonical amino acids can change the protein structure, causing considerably modified physical and chemical properties. Noncanonical amino acid analogs often act as cell growth inhibitors for expression hosts since they modify endogenous proteins, limiting in vivo protein production. In vivo incorporation of toxic noncanonical amino acids into proteins remains particularly challenging. Here, a cell-free approach for a complete replacement of L-arginine by the noncanonical amino acid L-canavanine is presented. It circumvents the inherent difficulties of in vivo expression. Additionally, a protocol to prepare target proteins for mass spectral analysis is included. It is shown that L-lysine can be replaced by L-hydroxy-lysine, albeit with lower efficiency. In principle, any noncanonical amino acid analog can be incorporated using the presented method as long as the endogenous in vitro translation system recognizes it.
Introduction
The genetic code is universal to the biosphere. It codes for a set of 20 canonical amino acids, which is sometimes extended by selenocysteine 1 or pyrrolysine 2 . It is the ribosome that translates the genetic code with the help of tRNAs into chains of amino acids that fold into proteins. The functional groups of the canonical amino acids, in combination with posttranslational modifications, contribute to an exceptionally wide range of protein function 3, 4 . In principle, functional limitations due to the limited set of canonical amino acids can be overcome by incorporating further, noncanonical amino acids (ncAAs) that enable new chemistries and new functionalities 3, 4 .
There are two complementary approaches for the incorporation of ncAAs: the site-or the residue-specific incorporation. The former method entails considerable technical difficulties, since the canonical set of aminoacyl-tRNA-synthetases (aaRS) and tRNAs must be expanded by an orthogonal aaRS-tRNA pair that must not interact with the endogenous translation machinery. Based on careful engineering, this approach incorporates the ncAAs as single point mutations at the desired protein sites. Site-specific incorporation of ncAAs is genetically encoded by a codon that is not assigned to a canonical amino acid (cAA), usually a stop codon [5] [6] [7] [8] [9] . This method entails changes in function at a given site rather than across the entire protein [10] [11] [12] [13] .
In contrast, residue-specific incorporation relies on erroneous recognition of the noncanonical amino acid by the canonical translation machinery. The incorporation occurs due to the lack of substrate specificity of the aaRS. The residue-specific incorporation of ncAAs, built on the work of Cohen and coworkers As natural aaRS generally prefer their cognate amino acid over an isostructural ncAA, efficient in vivo residue-specific incorporation usually requires an auxotrophic expression host not capable of synthesizing the canonical analog of the ncAA. The host cells are cultivated in growth medium that delivers only a low concentration of the analogous cAA. Its exhaustion in combination with the consecutive supplementation with the ncAA forces the expression host to incorporate the ncAA into the model protein at multiple, canonically prescribed sites. In contrast to the site-specific approach, this generally has a deep impact on the entire protein structure, leading to considerably modified physical and chemical properties of proteins 19, 20 . However, most of the ncAAs are growth inhibitors for the expression host 3 , as they are incorporated into many other proteins besides those of interest during recombinant gene expression. This clearly limits the in vivo approach. The in vivo incorporation of amino acids that are toxic or have strong influence on the protein structure remains particularly challenging. However, these molecules are among the most promising to engineer proteins with extraordinary functions.
One example is the toxic, noncanonical, naturally occurring L-canavanine (Can), an analog of L-arginine (Arg). It affects and blocks Arg associated regulatory and catalytic reaction pathways, and its presence in the living cell can lead to immediate death 3, [21] [22] [23] . Its incorporation into proteins at arginine positions can reduce protein stability [21] [22] [23] . Due to the resulting toxicity, expression of canavanine containing proteins in Escherichia coli (E. coli) and other common expression hosts remains a challenge. For these reasons, complete in vivo incorporation of Can at all Arg positions has appropriately been confirmed only once 24 , using an elaborated single-protein production system. However, Can has been proposed as an anti-cancer agent [25] [26] [27] , and as a stimulator for autoimmune diseases in humans 28 . Additionally, it is subject of various studies on its anti-metabolic, antibacterial, antifungal and antiviral properties 25 . These properties raise a demand for efficient and easy-to-perform methods to express Can containing proteins for pharmaceutic, medical and functional studies.
Although many problems that are connected to in vivo production can be circumvented using cell-free expression systems, in vitro residuespecific approaches have only been poorly explored. The cell-free residue-specific incorporation of an L-tryptophan analog 29 and multiple ncAAs 30 have been reported. These methods are based on the highly efficient T7 RNA polymerase. The T7 RNA polymerase entails bacteriophage-like transcription, thereby reducing genetic functionality in comparison to endogenous transcription.
The complete residue-specific incorporation of Can into a model protein at all Arg positions was recently reported 31 , using a cell-free expression system 32 . A slight modification of the same system enabled site-specific incorporation of different pyrrolysine analogs into a model protein via stop codon suppression 33 . The employed cell-free system [31] [32] [33] is based on an all E. coli transcription-translation system. Nevertheless, it enables protein expression as efficiently as in current bacteriophage systems (0.5 -1 mg/ml of recombinant protein) 32 , while retaining much of the original transcription-translation modularity.
In this work, a detailed protocol is provided on how the residue-specific incorporation of ncAAs can be realized, using this all E. coli cellfree system 32 . Additionally, further steps to prepare the expressed proteins for appropriate evaluation via HPLC-ESI mass spectroscopy are proposed. To expand the properties of this cell-free system, this work does not only refer to the published incorporation of Can 31 but also presents new data related to the noncanonical L-lysine analog L-hydroxy-lysine.
The following protocol for the residue-specific incorporation of ncAAs is an adaptation of a protocol recently published in JoVE
34
. The latter protocol describes how to perform highly efficient cell-free expression with standard amino acids. Furthermore, it presents the preparation of the crude cell free extract, the amino acid solution, the energy stock solution and the energy buffer used in this approach. The following protocol focuses on modified steps in comparison to the previous protocol in order to enable the residue-specific incorporation of ncAAs. Calibrated pipets, low-binding pipette tips and micro-centrifuge tubes are recommended for the preparation. In the following, IUPAC abbreviations for the amino acids are used.
Protocol
Caution! Please consult all relevant material safety data sheets (MSDS) before use. Several of the used chemicals are acutely toxic. Personal protective equipment is required (eyeshield, dust mask, gloves, lab coat, full length pants, closed-toe shoes) as well as working in a fume hood. 6. Prepare an amino acid solution that is composed of 19 cAAs except for the cAA (e.g., Arg) that is analogous to the ncAA (e.g., Can). Add each amino acid to a concentration of 6 mM, except for Leu (5 mM). 7. Prepare an amino acid mixture that contains 19 cAAs and the ncAA (e.g., Can) that substitutes the canonical one (e.g., Arg). Add each amino acid to a concentration of 6 mM, except for Leu (5 mM). To the last 1.35 ml volume, as a result of the split in step 1.2.4.3, add 50 µl of the 168 mM stock solution of the ncAA (e.g., Can). Label it "+ ncAA" (e.g., + Can). Thoroughly vortex and put back on ice. 1. Aliquot this 1.4 ml solution in volumes of 16 µl into reaction tubes. Note that this solution volume approximately leads to 85 aliquots. Label these aliquots "+ ncAA" (e.g., + Can). 2. Flash freeze the aliquots in liquid nitrogen and store at -80 °C. CAUTION! For safety, wear an eyeshield and Cryo-gloves to be protected from nitrogen splashes. NOTE: The 16 µl aliquot volumes used in the steps 1.2.5.1, 1.2.6.1 and 1.2.7.1 are slightly higher than required to account for losses due to pipetting.
Amino Acid Solution Preparation

Energy Buffer Preparation
NOTE: Each batch of crude extract is unique and requires optimized concentrations of Mg-and K-glutamate 34 . The crude extract aliquot volume depends on the protein concentration 34 . Use the provided calculation template (Supplemental Material 1) for different values. Find further instructions in Supplemental Material 1 figure legend, explaining how to employ this template.
1. Prepare and store at -80 °C the 14x energy solution and crude extract aliquots according to the unmodified protocol 34 . Calibrate the crude extract depending on the Mg-and K-glutamate concentrations for optimized expression efficiency 34 . NOTE: The final composition of 14x energy solution is: 700 mM HEPES (pH 8), 21 mM ATP, 21 mM GTP, 12.6 mM CTP, 12.6 mM UTP, 2.8 mg/ml tRNA, 3.64 mM CoA, 4.62 mM NAD, 10.5 mM cAMP, 0.95 mM folinic acid, 14 mM spermidine, 420 mM 3-PGA. 2. Thaw on ice the 100 mM Mg-glutamate stock solution, 3 M K-glutamate stock solution, 14x energy solution and 40% PEG-8000 to prepare the master mix. Keep them on ice. 3. Mix 9.18 µl of 100 mM Mg-glutamate stock solution, 3.06 µl of 3 M K-glutamate stock solution, 21.86 µl of 14x energy solution, 15.3 µl of 40%
PEG-8000 and 1.6 µl sterile ddH 2 O in a reaction tube. Thoroughly vortex this master mix after each addition, and keep it on ice. 4. Aliquot the master mix (51 µl) into volumes of 16 µl (3 aliquots) into reaction tubes. Frequently vortex the master mix during aliquoting. Flash freeze the aliquots in liquid nitrogen. NOTE: The 16 µl aliquot volume as well as the master mix volume are slightly higher than required to account for losses due to pipetting. 5. Use a strainer to collect the energy buffer tubes. Store the tubes at -80 °C. CAUTION! Wear an eyeshield and Cryo-gloves to be protected from nitrogen splashes. [40] [41] [42] . Store the DNA solution at -20 °C or directly use it for the cell-fee reaction preparation (steps 3.4.1, 3.4.2 and 3.4.3).
Preparation and Execution of Cell-free Reactions for Residue-specific Incorporation of ncAAs
2. Calibrate the cell-free expression efficiency depending on the used vector construct concentration according to the unmodified protocol 34 . Use the optimal concentration that leads to highest protein yields for the cell-free reaction preparation (steps 3.4.1, 3.4.2 and 3.4.3). NOTE: The preparation of cell-free reactions is exemplified using a 90 nM vector DNA stock solution that leads to a final vector concentration of 10 nM in the cell-free reaction and follows the above optimal values of Mg-and K-glutamate as well as the extract aliquot volume. Use the calculation template for different values. 3. Thaw on ice 3 crude extract aliquots each of 30 µl volume (prepared according to unmodified protocol 34 ), 1 amino acid solution aliquot labeled "+ cAA" (e.g., + Arg), 1 amino acid solution aliquot labeled "-cAA" (e.g., -Arg) and 1 amino acid solution aliquot labeled "+ ncAA" (e.g., + Can) (prepared in sections 1.2.5 -1.2.7), 3 energy buffers aliquots (prepared in section 2) and the vector DNA solution (prepared in section 3.1). NOTE: The crude extract is slightly viscous and it may contain air bubbles. Remove air bubbles by centrifuging at 10,000 x g for 30 sec at 4°C
. Put crude extract aliquots back on ice. Close the tubes and put them back on ice. Label all reaction tubes as "CFR(+cAA)" (e.g., CFR(+Arg)).
2. Prepare the negative control cell-free reaction (90 µl), where neither the cAA (e.g., Arg) nor the noncanonical analog (e.g., Can) are added. Close the tubes and put them back on ice. Label all reaction tubes as "CFR(-cAA)" (e.g., CFR(-Arg)).
3. Prepare the cell-free reaction (90 µl) that is supposed to residue-specifically incorporate the ncAA (e.g., Can) into the expressed model protein. Close the tubes and put them back on ice. For increased reaction volumes, accordingly aliquot in further volumes of 6 µl. Label all reaction tubes as "CFR(+ncAA)" (e.g., CFR(+Can)).
5. Incubate all tubes at 29 °C O/N. NOTE: Only small reaction volumes enable adequate oxygen diffusion into the reaction that is crucial for highly efficient protein expression. Reaction volumes greater than 10 µl require active oxygenation through agitation 34 . For large volumes, split the reaction into volumes smaller than 15 µl. 6. After cell-free expression, pool all identically composed split cell-free reactions of 6 µl. First, pool all 15 split cell-free reactions of 6 µl labeled "CFR(+cAA)" (e.g., CFR(+Arg)). Then, pool all 15 split cell-free reactions of 6 µl labeled "CFR(-cAA)" (e.g., CFR(-Arg)). Finally, pool all 15 split cell-free reactions of 6 µl labeled "CFR(+ncAA)" (e.g., CFR(+Can)). For increased reaction volumes, accordingly pool further volumes of 6 µl. SDS-PAGE to ensure appropriate gel migration and to avoid saturation after staining. In order not to waste too much sample, dilute 1 µl of cell-free reaction in 4 µl of sterile ddH 2 O. Prepare the dilution in reaction tubes, thoroughly vortex and shortly spin the liquid down with a mini centrifuge for 2 -3 sec at 2,000 x g. 3. Add 5 µl of 2x loading buffer to 5 µl of diluted cell-free reaction. Thoroughly vortex and spin down with a mini centrifuge for 2 -3 sec at 2,000 x g. NOTE: Here, after addition, the biomolecules are dissolved in 62.5 mM Tris/Cl -, 10% glycerol, 2% SDS, and 0.0025% bromophenol blue at pH 6.8, a typical composition. Using other loading dyes that lead to slightly different dilution conditions may be suitable as well. 4. Thoroughly vortex the protein standard and transfer 15 µl of it into a reaction tube.
Preliminary Evaluation via SDS-PAGE
NOTE: Depending on gel size and for other protein standards, the recommended volume can differ from the above. NOTE: Using His-binding buffer is recommended. However, cell-free reaction medium can be a starting material as long as the model protein is soluble, pH is between 7.5 -8, imidazole/His concentration is < 10 mM, concentration of strong reducing agents is < 15 mM and no metal-chelating agents are present. If your mixture volume exceeds 300 µl, split it into equal volumes and aliquot theses volumes into different reaction tubes for the following purification steps. 2. Prepare the column system. Thoroughly vortex the stock solution of the His-affinity gel until the gel resin is completely dissolved.
Transfer 250 µl of gel resin into the column. Use a 1 ml pipette tip for the viscous gel resin. Place the column into a collection tube. Centrifuge column/collection tube for 5 -10 sec at 13,000 -15,000 x g. Discard the flow-through and place the column back into the collection tube. Repeat step 4.2.1.6 and centrifuge again for 5 -10 sec at 13,000 -15,000 x g. 8. Place the column into a standard 1.5 ml reaction tube. Add 150 µl of elution buffer and resuspend the gel resin by tapping and gentle vortexing. Reduce the volume to 100 µl for higher purified model protein concentrations after elution in the next step 4.2.1.9. NOTE: The total abundance of purified model protein may be reduced due to possible incomplete elution of all gel resin-bound proteins, if the elution buffer volume is reduced. 9. Centrifuge column/reaction tube for 5 -10 sec at 13,000 -15,000 x g to dilute the purified protein in the elution buffer. If split before, pool all solutions into one stock solution. 10. Before executing the buffer exchange, determine the protein concentration using standard methods, e.g., the Bradford assay 47, 48 . NOTE: For an appropriate HPLC-ESI mass spectroscopy (section 4.4), use optimal protein concentrations that are usually about 0.5 mg/ml with required volumes of 20 -50 µl. If the concentration is below 0.2 mg/ml, concentrate the protein solution after the buffer exchange using a spinning vacuum concentrator. In this case, first read section 4.3.8 to appropriately adapt the exchanging buffer.
Buffer exchange for HPLC-ESI mass spectroscopy
NOTE: Exchange the His-tag elution buffer to avoid high background noise in mass spectroscopic analysis due to high concentration of imidazole (> 150 mM) and other salts such as NaH 2 PO 4 (> 300 mM) or NaCl (> 50 mM) 49 . The following buffer exchange protocol uses a prehydrated gel filtration spin column system. It is identically executed for native or modified model proteins. Thus, it is generally described on the basis of one single cell-free reaction. Note that there are other easy-to-perform buffer exchange methods, e.g., mini-dialysis cartridges.
1. Prepare 100 ml of protein storage buffer (50 mM Tris-Cl pH 8, 100 mM NaCl, and 10% glycerol). Weigh out into an autoclavable 100 ml bottle 605.7 mg Tris-Base, 584.4 mg NaCl and add 10 ml of glycerol. Fill up to approximately 80 ml and adjust the pH value to 8 by adding NaOH. Steadily check the pH value with a pH meter. Finally, fill up to the 100 ml mark. NOTE: Use this buffer to stabilize a wide range of model proteins and not to disturb mass spectroscopic analysis, as long as HPLC is performed prior to the mass spectroscopic measurement. However, depending on the nature of the expressed model protein, use other buffers that might be better suitable. If your target protein is not stable at pH 8, adjust the pH accordingly. Do not use higher glycerol concentrations. 2. Warm up the gel filtration spin columns for at least 15 min to RT. 3. Resuspend the prehydrated gel by gentle tapping or vortexing and remove air bubbles. 4. First remove the bottom cap, and then take the top cap away. Place the column into a wash tube (at least 2 ml). Transfer the column/ wash tube into the centrifuge. Each column possesses an orientation mark. Centrifuge at 1,000 x g for 2 min to remove the gel storage buffer. Discard the flow-through. NOTE: Pay attention to proceed in this order. Ensure that the column has the same orientation in all further centrifugation steps. 5. Add up to 400 µl of the protein storage buffer. Centrifuge for 2 min at 1,000 x g. Repeat this to completely load the protein storage buffer into gel. Carefully add up to 100 µl of the solution of the purified model protein. Pipette directly onto the center of the gel bed. NOTE: Solution volumes of purified proteins, particularly of modified proteins, might be higher. Split such solutions over several buffer exchange columns. Proteins must have molecular weights higher than 5 kDa for this kind of buffer exchange. 6. Place the column into a collection tube and centrifuge for 2 min at 1,000 x g.
NOTE: This step leads to the dilution of the purified model protein in the protein storage buffer. If split before, pool all solutions into one stock solution. 7. Flash freeze the protein solution in liquid nitrogen and store at -80 °C or directly analyze it via HPLC-ESI mass spectroscopy 50 (section 4.4). CAUTION! Wear an eyeshield and Cryo-gloves to be protected from nitrogen splashes. 8. Perform the following steps of the protocol to concentrate the protein solution using a spinning vacuum concentrator that carefully evaporates the solvent 51 . NOTE: These steps are required if the protein concentration is too low for HPLC-ESI mass spectroscopy (< 0.2 mg/ml). The solution volume and model protein concentration is roughly the same before and after buffer exchange. The concentration process is described by means of the following example: After His-tag purification, the model protein is dissolved in 100 µl His elution buffer (step 4.2.1.9) and has a concentration of 0.07 mg/ml (step 4.2.1.10).
1. To ensure that the protein concentration and the solution volume are after evaporation at least 0.2 mg/ml and 20 µl, respectively, dilute, before buffer exchange, the protein storage buffer prepared in step 4. 
Representative Results
This protocol guides through the cell-free residue-specific incorporation of ncAAs into model proteins. It proposes SDS-PAGE for a preliminary evaluation of the incorporation experiment and further steps to prepare the model proteins for an appropriate HPLC-ESI mass spectroscopic analysis.
Here, representative results of the cell-free residue-specific incorporation of the Arg analog Can, as well as the Lys analog L-hydroxy-lysine (Hyl) are presented. The different amino acid solutions, the energy buffer, the vector DNA coding for the model protein and cell-free reactions are prepared as described above. The reference cell-free reaction is provided with the amino acid solution consisting of the 20 cAAs. For each experiment, a negative control cell-free reaction is supplied with the amino acid solution that lacks the canonical analog of the ncAA in question.
For each approach, one cell-free reaction expresses the model protein in the presence of the amino acid solution, where the cAA is substituted by the noncanonical analog. His-tag purification, buffer exchange and HPLC-ESI mass spectrometric analysis are executed according to the above described protocol.
The model protein is the C-terminal His-tagged deGFP 32 , a truncated version of EGFP 53 . Its one letter amino acid sequence can be found in (Supplemental Material 2). This model protein contains 6 Arg and 18 Lys positions, respectively. The expression vector is pBEST-OR2-OR1-Pr-UTR1-deGFP-T500.
In the case of complete incorporation of the ncAA, one can assume that the negative control reaction does not express deGFP, since one of the 20 cAAs is missing. Contrary, deGFP must be detectable in the other two reactions: the native one in the reference cell-free reaction and the modified protein in the cell-free reaction that is provided with the ncAA. Figure 1A shows the preliminary SDS-PAGE evaluation of the Can incorporation experiment. The reference cell-free reaction has the highest deGFP expression level. In the cell-free reaction that is provided with Can, deGFP is expressed at slightly lower concentration. No deGFP expression can be detected in the negative control. This SDS-PAGE result is a good indication for a successful incorporation of Can into the target protein deGFP.
To prove the hypothesized complete incorporation of Can into deGFP, both purified model proteins, visualized in Figure 1B , are analyzed through HPLC-ESI mass spectroscopy. Figure 1C shows the deconvoluted mass spectra of the purified deGFP molecules. The deconvoluted mass of deGFP that is expressed in the reference cell-free reaction is 26,192.8 Da. For deGFP expressed in the Can containing cell-free reaction a mass of 26202.5 Da appears. The expected masses for the native deGFP6Arg and the modified deGFP6Can with Arg being fully replaced by Can are 26, 193 Da and 26,204 Da, respectively. The mass difference of 1.5 Da for deGFP6Can is within the error of spectrum deconvolution. Thus, the full incorporation of Can into deGFP at all 6 Arg positions is confirmed.
The two peaks of reduced intensity correspond to the native deGFP6Arg and modified deGFP6Can that did not attain their mature fluorophore. The fluorophore is autocatalytically generated by elimination of a H 2 O molecule, followed by oxidation. This leads to a mass increased by 20 Da if this process does not proceed.
. The cell-free expression efficiency is optimized depending on the vector DNA construction concentration. The volumes of the energy buffer components vary as function of optimized Mg-and K-glutamate concentrations in order to enable high yields of the cell-free expressed model protein.
A preliminary evaluation of the incorporation experiment can be obtained by performing SDS-PAGE of the unpurified cell-free reaction medium. For a more detailed analysis, HPLC-ESI mass spectroscopy is proposed as a means to check for complete, residue-specific incorporation of the ncAA. As a preparation for the latter, spin column systems are used to enable His-tag purification and buffer exchange with the small volumes that we use in this protocol.
Including HPLC-ESI mass spectroscopy, the entire protocol can be performed within 2 days. It does not include any particularly critical steps. However, concentration optimizations of Mg-and K-glutamate as well as of vector DNA are crucial in order to express high yields of the model protein. The use of the highly efficient expression vector pBEST-OR2-Or1-Pr-UTR1-gene_of_model_protein-T500 is strongly recommended. Elution of His-tagged proteins is usually due to high concentration of imidazole (> 150 mM) and other salts such as NaH 2 PO 4 (> 300 mM) or NaCl (> 50 mM) that generate high background noise in mass spectroscopic analysis 49 . Exchange of such elution buffers with a suitable protein storage buffer stabilizes the model protein and drastically reduces background noise during mass spectroscopic analysis.
As a result, Can replaces Arg at all six positions within the model protein. In the expression system, no Arg residues can be detected. This simplifies the residue-specific incorporation of Arg analogs compared to other expression systems that require further depletion strategies 29, 30 . The presented cell-free approach circumvents the inherent limitations of in vivo approaches that are due to Can toxicity, or the strong dependency on mRNA sequence in single protein production strategies 24, 31 . Contrary to the employed in vitro system, in vivo cleavage of Can to homoserine and hydroxyguanidine does occur 31 .
However, the cell-free system retains a sufficient amount of Lys to compete with analogs such as Hyl. The HPLC-ESI mass spectroscopic analysis shows that the model protein contains both, the canonical as well as the noncanonical analog in different proportions. The residuespecific incorporation of Lys is possible in general, but for complete substitution, further depletion strategies, or specially engineered aaRS and tRNA optimized for the recognition of ncAAs need to be developed.
We achieved excellent yields of cell-free expressed, modified model proteins by adding the ncAA at the same concentration as the canonical ones. The incorporation efficiency depends on the nature of the ncAA to be incorporated. Even higher yields might still be realizable by optimizing the concentration of the ncAA.
The presented results demonstrate the applicability of the employed system for the residue-specific incorporation of ncAAs as long as they are accepted by the canonical endogenous translational system. For the residue-specific incorporation of specific ncAAs, one further needs to check if the residues of the analogous cAA disturb the expression system.
Cell-free transcription-translation systems can be engineered from different organisms to respond to different demands 54 . The all E. coli transcription-translation machineries of the here presented cell-free system enable the usage of bacteriophage and E. coli promoters, and they can act in parallel or consecutively in cascades 55 . The general applicability and usability make the method a potent tool for further research in amino acid toxicity and therapeutic application.
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